A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

Inclusion Criteria:

• The participant has a diagnosis of asthma of at least 6 months duration.

• Participants currently receive a beta-agonist (eg, salbutamol [albuterol] or ICSalbuterol or ICS-formoterol) as rescue medication with or without asthma controllermedication.

• If female, a participant is currently not pregnant, breastfeeding, or attempting tobecome pregnant (for at least 30 days before the screening visit and throughout theduration of the trial), or is of non-childbearing potential.

NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

• The participant has a history of life-threatening asthma defined as any history ofsignificant asthma episode(s) requiring intubation, associated with hypercapnia,respiratory arrest, hypoxic seizures or an asthma related syncopal episode.

• The participant has had an upper or lower respiratory tract infection within 2 weeksor has had a confirmed case of COVID-19 within 6 weeks prior to Visit 1. Symptoms ofthe infection(s) must be completely resolved prior to entering screening.

• The participant is a current smoker and/or has a history of ≥10 pack years historyof smoking. A current smoker is defined as any participant who has used any form oftobacco product (including oral) within the past 6 months, or any orally inhaledproducts including but not limited to cigarettes, beedis, vaping/ e-cigarettes,hookah/waterpipes, or marijuana. Note: participants with a positive urinary cotininetest will be excluded.

• The participant has another confounding underlying lung disorder (eg, chronicobstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasiswith the need of treatment, cystic fibrosis, pulmonary fibrosis), or participantswith a diagnosis of asthma COPD overlap syndrome.

NOTE- Additional criteria apply, please contact the investigator for more information